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1. INTRODUCTION AND PURPOSE 
This document details the rules proposed and the presentation that will be followed, as closely as 
possible, when analysing and reporting the main statistical results from the Travel to Work study. 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical 
practice, and that interpretation of a priori and post hoc analyses respectively is appropriate. 
2. Explain in detail how the data will be handled and analysed to enable others to perform the 
actual analysis in the event of sickness or other absence. 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but 
fall outside the scope of this analysis plan (although such analyses would be expected to follow good 
statistical practice). 
The analysis strategy will be made available if required by journal editors or referees when the main 
papers are submitted for publication.  Additional analyses suggested by reviewers or editors will, if 
considered appropriate, be performed in accordance with the analysis plan, but if reported the 
source of such a post-hoc analysis will be declared. 
Amendments to the statistical analysis plan will be described and justified in the final report of the 
trial. 
1.1 RATIONALE  
Physical inactivity increases the risk of many chronic diseases including coronary heart disease, type 
2 diabetes, obesity and some cancers1. Increasing physical activity levels, particularly among the 
most inactive, is an important aim of current public health policy in the UK2. There is also increasing 
interest in the relationship between time spent sedentary and poor health outcomes3 and 
consequently UK health guidelines recommend that adults should minimise the amount of time 
spent sedentary (sitting) in addition to increasing physical activity.  
In the UK, there are substantial opportunities to increase walking by replacing short journeys 
undertaken by car. For example, the 2011 National Travel Survey showed 22% of all car trips were 
shorter than two miles in length, while 18% of trips of less than one mile were made by car4. An 
opportunity for working adults to accumulate the recommended moderate activity levels is through 
the daily commute and, in addition, replacing the car for short journeys is likely to reduce sedentary 
time. Experts in many World Health Organisation (WHO) countries agree that significant public 
health benefits can be realised through greater use of active transport modes5. Furthermore, cost 
benefit analysis for the UK Department for Transport suggests the ratio of benefits to costs are high6. 
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NICE public health guidance on workplace health promotion concluded that although schemes exist 
to encourage employees to walk or cycle to work, little is known about their impact7. Few studies 
used robust data collection methods to measure the impact of workplace interventions on 
employees’ physical activity levels, with most using self-report. There was also a lack of information 
about how interventions are influenced by the size and type of workplace and the characteristics of 
employees. 
In 2011, the National Institute for Health Research Public Health Research (NIHR-PHR) programme 
funded the Walk to Work feasibility study (Project 10/3001/04) which incorporated a Phase I 
development of a behavioural intervention followed by a Phase II exploratory trial in 17 workplaces 
in Bristol8. The intervention was tested in small, medium-sized and large workplaces, used objective 
measures of physical activity, and included process evaluation and an assessment of costs. Results 
from the feasibility study demonstrated that the intervention and its evaluation were feasible and 
funding was granted for a full-scale cluster randomised controlled trial (NIHR- PHR - 13/117/01)9. 
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2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
This is a summary of the study design as described in the study protocol paper with the single 
purpose of ensuring an informed statistical analysis. For all other purposes reference MUST be 
made to the current version of the protocol. 
The main aim of the Travel to Work trial is to examine the effectiveness, cost effectiveness and 
generalisability of a workplace-based ‘Walk to Work’ intervention. 
2.1. TRIAL OBJECTIVES AND AIMS 
2.1.1. PRIMARY OBJECTIVE 
1. Does the intervention lead to an increase in daily minutes of moderate to vigorous physical 
activity (MVPA) after one year compared with the control group? 
 
2.1.2. SECONDARY OBJECTIVES 
1. Does the intervention lead to an increase in overall physical activity compared with the control 
group? 
2. Does the intervention decrease the daily minutes of sedentary time, compared with the 
control group? 
3. Does the intervention lead to an increased number of journeys where walking to work is the 
major mode of travel, compared with the control group?  
4. Does the intervention increase the MVPA due to walking on the commute, compared with the 
control group? 
2.1.3. ECONOMIC OBJECTIVES 
1. What are the intervention costs to participating employers and employees? 
2. Does the intervention lead to increased or decreased costs in terms of healthcare use, 
commute costs and productivity losses? 
3. Does the intervention lead to improved wellbeing as measured by the ICECAP-A 
questionnaire? 
2.2. TRIAL DESIGN AND CONFIGURATION 
The study is a multi-centre cluster randomised controlled trial, aiming to recruit 84 workplaces in 
south-west England and south Wales, and incorporates process and economic evaluations. The 
intervention will be implemented in 42 workplaces; and 42 workplaces will be randomised to the 
control arm. 
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2.3. ELIGIBILITY CRITERIA 
2.3.1. INCLUSION CRITERIA (ALL CRITERIA MUST BE MET) 
1. Employees in participating workplaces in urban and suburban areas of south-west England 
and south Wales will be eligible to take part. 
2.3.2. EXCLUSION CRITERIA (IF ANY CRITERION MET) 
1. Employees who already always walk/cycle to work 
2. Employees who are due to retire before the one year follow-up data collection 
3. Employees who are disabled in relation to walking 
4. Employees for whom daily driving is a key part of their role (e.g. sales reps) 
5. Workplaces with a large proportion of short-term/zero hour contracts as follow-up data may 
not be achievable 
6. Workplaces with plans to significantly downsize/relocate during the study period 
2.4. DESCRIPTION OF INTERVENTION 
Workplace ‘Walk-to-Work promoters’ will be identified (volunteers, or nominated by participating 
employers) and trained by members of the research team about the benefits of walking during the 
daily commute and how to promote increased walking either by walking the entire route or mixing 
walking with other transport modes. Training will take place during the working day on site, or at a 
group external event, as appropriate to the needs of the workplace. The Walk-to-Work promoters 
will be given resource packs and trained to access relevant websites and toolkits. They will also be 
trained in the use of specific behaviour change techniques that form the basis of the intervention, 
including: providing information on the link between walking and health; prompting intention 
formation; identifying barriers to walking and ways to overcome them; prompting goal setting; 
prompting self-monitoring; identifying social support and encouragement; reviewing goals, and; 
relapse prevention. There is evidence that these techniques are effective in achieving behaviour 
change10,11 and can be effectively delivered by non-specialists. There will be a maximum of 25 
participants to each promoter. Additional booklets will be provided for employers/managers with 
information and ideas of how the workplace can support increased walking during the daily 
commute. 
Participating employees will be contacted by the Walk-to-Work promoter and given a Walk-to-Work 
pack including an information booklet, travel diary and pedometer. Goals for incorporating walking 
into the journey to and from work will be set. Further encouragement will be provided through four 
contacts from the Walk-to-Work promoter over the following 10 weeks (face-to-face, email or 
telephone as appropriate to the workplace size, resources and work routines).  
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2.5. RANDOMISATION PROCEDURES 
Randomisation will take place at the level of the workplace. Employers in workplaces expressing an 
interest will be asked to complete a short questionnaire. From the results of these questionnaires 
the randomisation will be carried out by creating pairs (or triples) of workplaces with similar 
characteristics such as the size of the company (micro, small, medium and large), location (Swansea 
(including Newport and Neath Port Talbot), Bath (including Swindon), Bristol (including South 
Gloucester) and type of business (using UK-SIC category). Assignment of workplaces will be carried 
out by the Bristol Randomised Trials Collaboration (BRTC) after pairing of workplaces with one 
workplace randomised to control and one (or two in a triple) to intervention using a concealed 
randomly computer generated allocation to minimise selection bias.  
Given the nature of the intervention it is not possible to blind participants following randomisation. 
 
2.6. SAMPLE SIZE AND JUSTIFICATION 
Using the findings from the feasibility study, the sample size for the full scale trial was based on an 
average cluster size of 8, an ICC of 0.15 and participant attrition of 25%.  
The calculation needed to allow equal numbers of workplaces between the intervention and control 
groups. We calculated that we needed 339 per study arm to detect a 15% difference in MVPA levels 
(equal to a difference of 0.36 standard deviations) with 80% power at the 5% significance level. 
Therefore 678 employees were required from 84 workplaces. The intervention would be 
implemented in 42 of the 84 workplaces; while the remaining 42 formed the control arm. 
 
2.7. TRIAL COMMITTEES 
The Travel to Work trial has a Trial Steering Committee, chaired by Dr David Ogilvie, Programme 
Leader, MRC Epidemiology Unit, University of Cambridge. Dr Obi Ukoumunne, Associate Professor in 
Medical Statistics, University of Exeter, is the independent statistician and Dr Emma Frew PhD, Dr 
Emma Frew, Reader in Health Economics, Institute of Applied Health Research, University of 
Birmingham, is the independent health economist for the Trial Steering Committee. 
2.8. OUTCOME MEASURES 
Raw accelerometer data will be downloaded using Actilife 6 software (ActiGraph LLC) and reintegrated 
to ten-second epochs for analysis and matching with GPS data. Reintegrated accelerometer data will 
be processed using Kinesoft (v3.3.75; KineSoft, Saskatchewan, Canada) data reduction software to 
generate outcome variables. Continuous periods of 60 minutes or more of zero values will be 
considered to be “non-wear” time and removed. The outcome variables of total physical activity 
volume (mean daily accelerometer counts per minute (cpm), time spent in moderate to vigorous 
physical activity (MVPA) and sedentary time, will be defined using validated thresholds (MVPA ≥ 
1952 cpm; sedentary <100 cpm)12.  
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For the primary outcome analysis and the secondary outcome analyses of overall physical activity and 
sedentary time, participants are required to provide three days of valid accelerometer data of at least 
600 minutes of accelerometer data. Participants are required to provide at least one valid day of 
accelerometer and GPS data to be included in the secondary outcome analyses of modal shift and 
daily MVPA of the commute.  
Accelerometer and GPS data will be combined (accGPS) based upon the timestamp of the Actigraph 
data. For measurement of the journeys to and from work, the participant’s workplace and home will 
be geocoded using the full postcode, and imported into a Geographical Information System (ArcMap 
v10.2.2). The merged accGPS files will then imported into ArcMap and journeys to and from work 
visually identified and segmented from other accGPS data using the “identify” tool. Journeys will be 
identified as a continuous (or near-continuous) sequence of GPS locations between the participant’s 
home and workplace, and thus will include trips to other destinations (e.g. supermarkets) if taken as 
part of the journey to or from work. The data will also be visually analysed by the researcher to 
categorise participants’ daily mode of travel to work over the measurement week using the variables: 
counts per 10 seconds, changes to sum of SNR, speed (km/hr) and GIS location. Where accelerometer 
and GPS data is not available, self-report data in the travel diaries will be used to define mode of 
transport on the commute.  
Cycling journeys will be excluded from all analyses due to the inability of waist worn accelerometers 
to accurately record physical activity during cycling. For participants who used a mixed mode of travel 
(e.g. car and train) for a journey, the mode of transport of the greatest distance was considered to be 
their mode for that journey. If the modes were of equal distance, the data will be coded as the most 
active mode of travel. When an outward/return journey is missing, it will be assumed to be via the 
same mode of travel as the outward/return journey on the same day. 
The economic evaluation will be presented as a cost-consequence analysis whereby costs and 
consequences are tabulated but no attempt will be made to combine results. A broad perspective will 
be taken to include employer, employee and health care costs and individual wellbeing over the one 
year follow-up period. Discounting will not be performed given the one year follow-up period. 
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Outcomes, data collection methods and timing 
Outcome Method Timing 
PRIMARY OUTCOME 
i) Daily minutes of MVPA  Accelerometers Baseline data collection (DC1) 
and 1 year follow-up (DC3) 
SECONDARY OUTCOMES 
ii) Overall level of physical 
activity (cpm) 
Accelerometers DC1, DC3 
iii) Daily minutes of sedentary 
time 
Accelerometers DC1, DC3 
iv) Daily minutes of moderate 
to vigorous activity during the 
commute (Mean MVPA over 
the number of valid working 
follow-up days completed) 
Accelerometers and GPS 
Travel diaries 
DC1, DC3 
v) Modal shift (number of 
journeys, when walking was 
main mode of travel to/from 
work) 
Accelerometers and GPS 
Travel diaries 
DC1, DC3 
ECONOMIC OUTCOMES   
vi) Commuting time and costs Self-reported in the participant 
travel diaries 
DC1, DC3 for a one week period 
vii) Health care resource use Self-reported in participant 
questionnaires 
DC1 for the past 4 weeks, DC2 
(post-intervention) & DC3 
during the past 3 months 
viii) Productivity and days off 
from work 
Self-reported in participant 
questionnaires 
DC1 for the past week, DC3 
during the past 12 months 
ix) ICECAP-A Participant questionnaires DC1, DC2, DC3 
vi) Costs to employers of 
implementing the scheme 
Employer questionnaires  DC2 
xi) Overall workplace absentee 
rates 
Pro forma sent to employers Post DC3 for the 12 months 
between DC1 and DC3 
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2.8.1. PRIMARY OUTCOME 
 
2.8.2. SECONDARY OUTCOMES 
Secondary Outcome Type Data Analysis 
ii) Overall physical 
activity (mean counts 
per minute over the 
number of valid 
follow-up days 
completed, max. 7 
days) 
Continuous Linear Regression (mixed-effects) 
Covariates:- 
- Treatment arm 
- Size of the company (categorical) 
- Location of the company (categorical) 
- Type of business (categorical) 
- Baseline overall physical activity  
- Workplace as a random effect 
iii) Sedentary time 
(mean minutes per 
day over the number 
of valid follow-up 
days completed, max. 
7 days) 
Continuous Linear Regression (mixed-effects) 
Covariates:- 
- Treatment arm 
- Size of the company (categorical) 
- Location of the company (categorical) 
- Type of business (categorical) 
- Baseline sedentary time  
- Accelerometer wear-time (categorical)  
- Workplace as a random effect 
iv) Daily minutes of 
moderate to vigorous 
activity during the 
commute (mean 
MVPA over the 
number of valid 
working follow-up 
days completed, max. 
7 days)  
Continuous Linear Regression (mixed-effects) 
Covariates:- 
- Treatment arm  
- Size of the company (categorical) 
- Location of the company (categorical) 
- Type of business (categorical) 
- Baseline daily minutes of moderate to vigorous activity 
during the commute  
- Workplace as a random effect 
v) Number of 
journeys when 
Categorical  Negative binomial regression (zero-inflated if appropriate) 
with an exposure variable of number of valid journeys, 
Primary outcome Type  Data Analysis 
i) Daily minutes of 
moderate to vigorous 
activity (Mean 
minutes of MVPA 
over the number of 
valid follow-up days 
completed, max. 7 
days) 
Continuous Linear Regression (mixed-effects) 
Covariates:- 
- Treatment arm  
- Size of the company (categorical) 
- Location of the company (categorical) 
- Type of business (UK SIC category) 
- Baseline MVPA 
- Accelerometer wear-time (categorical)  
- Workplace as a random effect 
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walking was the 
major mode of travel 
to and from work 
(model shift, max. 14 
journeys) 
incorporating robust standard-errors to accommodate 
variation between workplaces 
Covariates:- 
- Treatment arm 
- Size of the company (categorical) 
- Location of the company (categorical) 
- Type of business (categorical) 
- Baseline number of journeys when walking was the 
major mode of travel to and from work  
 
2.8.3. ECONOMIC COSTS AND OUTCOMES 
 
Economic/cost 
outcome 
Item Valuation Data Analysis 
Intervention 
cost 
Trainer time 
Unit cost estimated using 
basic salary, national 
insurance and 
superannuation, or using the 
trainer’s day rate. 
Intervention cost presented as 
a cost per workplace and a cost 
per participating employee. 
Costs will also be stratified by 
workplace size. 
Employer 
cost 
Employee time: Unit cost 
estimated by dividing the 
upper quartile weekly 
earnings by the median 
number of hours worked per 
week from the ASHE18. 
Employee 
cost 
Employee reported travel cost 
to promoter training. 
Training 
materials 
Printing costs of employee 
and promoter booklets. 
Pedometer cost. 
Health care 
use 
Primary care Resource use multiplied by 
unit costs from the Unit Costs 
of Health and Social Care13. 
Total health care cost 
estimated for the past 3 
months at 1 year follow-up. 
Regression 
Covariates:- 
- Treatment arm 
- Size of the company 
(categorical) 
- Location of the company 
(categorical) 
- Type of business 
(categorical) 
- Baseline health care cost 
in the last 4 weeks 
- Workplace as a random 
effect 
Secondary 
care 
Resource use multiplied by 
unit costs from the NHS 
reference costs14. 
Prescribed 
medications 
Resource use multiplied by 
unit costs from the British 
National Formulary15. 
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Commute cost 
Car travel Time converted to mileage16 
and valued using AA Schedule 
of Motoring Costs17 to 
estimate average daily cost. 
Average daily commuting cost 
at 1 year follow-up. 
Regression 
Covariates:- 
- Treatment arm 
- Size of the company 
(categorical) 
- Location of the company 
(categorical) 
- Type of business 
(categorical) 
- Baseline average daily 
commute cost 
- Workplace as a random 
effect 
Permits and 
passes 
Employee reported cost and 
duration of permits and 
passes used to estimate the 
average daily cost. 
Employee 
daily 
expenses 
Presented as the average 
daily cost. 
Productivity 
costs 
Self-assessed 
productivity 
Employee reported 
productivity based on the 
extent to which health 
problems affected 
productivity in the past 3 
months measured on a 10-
point scale. Converted to 
wages using median weekly 
earnings18 assuming a 1-point 
decrement on the scale 
equates to a 10% loss in 
earnings. 
Total productivity costs in the 
past 3 months at 1 year follow-
up. 
Regression 
Covariates:- 
- Treatment arm 
- Size of the company 
(categorical) 
- Location of the company 
(categorical) 
- Type of business 
(categorical) 
- Baseline productivity 
costs over the past week 
- Workplace as a random 
effect 
Days of work 
missed 
Employee self-reported 
number of days of work 
missed in the last 3 months. 
Converted to wages using 
median weekly earnings18. 
Employee 
quality of life 
Estimated 
using the 
ICECAP-A 
ICECAP-A tariff scores 
estimated from questionnaire 
results and the ICECAP-A 
tariff19 
ICECAP-A tariff score at 1 year 
follow-up. 
Regression 
Covariates:- 
- Treatment arm 
- Size of the company 
(categorical) 
- Location of the company 
(categorical) 
- Type of business 
(categorical) 
- Baseline ICECAP-A tariff 
score 
- Workplace as a random 
effect 
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2.9. INTERIM ANALYSIS 
 
There are no pre-defined formal stopping rules. The trial may be prematurely discontinued by the 
Sponsor, Chief Investigator, Regulatory Authority or Funder on the basis of new safety information or 
for other reasons given by the Trial Steering Committee, regulatory authority or ethics committee 
concerned. 
 
In the unlikely event that participants in the intervention arm experience a large number of adverse 
events, compared with the control arm, the trial may be stopped.  
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3. GENERAL ANALYSIS CONSIDERATIONS 
 
3.1. STATISTICAL ANALYSIS 
 
STATA will be used for all statistical analyses for this trial. 
3.1.1 PRIMARY OUTCOME ANALYSIS 
The primary analysis will be on an Intention to Treat (ITT) basis. The primary outcome measure of 
MVPA (mean minutes per day) at one year follow-up (measured on a continuous scale) will be 
compared between the intervention and control groups using multivariable linear regression, with 
covariates: treatment arm, baseline MVPA, accelerometer wear-time, size of the company, location, 
type of business and workplace as a random effect.  
Assumptions: 
#1 Continuous dependent variable (MVPA is numerical) ✓ 
#2 One or more independent variables, can be categorical or continuous (Group + Covariates) ✓ 
#3 Linear relationship between each independent variable vs. MVPA and collectively vs. MVPA 
[CHECK: Scatter plots and partial regression plots] 
#4 Homoscedasticity [CHECK: Scatter plot of residuals] 
#5 No outliers [CHECK: using plots in Stata] 
#6 Normally distributed residuals [CHECK: Histogram and P-P, Q-Q plots] 
 
3.1.2 SECONDARY OUTCOME ANALYSES 
The secondary outcome analyses will be analysed on an ITT basis. The covariates are described in 
Section 2.8.2.  
1) Overall physical activity (counts per minute) – multivariable linear regression [Assumptions 
above] 
2) Sedentary time (minutes per day) – multivariable linear regression [Assumptions above] 
3) Modal shift (number of journeys when walking was the major mode of travel to and from 
work) – negative binomial regression [Assumptions above] 
4) MVPA due only to the commute (daily minutes of MVPA) – multivariable linear regression 
[Assumptions above]  
3.2. ANALYSIS POPULATIONS 
The primary analysis set is all randomised workplaces and employees within south-west England and 
south Wales that meet the inclusion criteria. Exclusion criteria can be found in Section 2.3.2. 
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3.3. DERIVED VARIABLES 
See Section 10 and Protocol: Coding commute to work and assessment of mode of commute to work.  
 
3.4. PROCEDURES FOR MISSING DATA 
A sensitivity analysis will be conducted for the impact of missing data on the primary analysis (if 
required), using the most appropriate imputation technique. We will conduct this analysis if around 
20% of the data needed is missing for the primary analysis. 
In order to more appropriately classify the missingness mechanism of the data the distribution of 
baseline data will be compared for those missing either the primary outcome, or covariates needed 
for the primary analysis model, and those that are not missing the data.  If we are able to assume 
that the data is “Missing at Random (MAR)”, multiple imputation will be used. Packages, such as 
REALCOM Impute, that incorporate methods for clustered data and multi-level analyses will be used.   
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4. RECRUITMENT AND RETENTION 
4.1. DISPOSITION 
A flow of workplaces, and participants, through the trial will be summarised in a CONSORT diagram.  
 
 
 
  
Workplaces randomised (N= ) 
Participants (N= ) 
 
Control 
Workplaces N =  
Participants N =  
Baseline data collection 
Accelerometers (n=, %); GPS (n=, %); Travel 
diaries (n=, %); questionnaires (n=, %) 
 
Withdrawn 
Workplaces N =  
Participants N =  3 month follow up  
Participants N =  ( %) 
3 month follow up  
Participants N = ( %) 
12 month follow up  
Workplaces N =  
Participants N =  
Accelerometers (n=, %); GPS (n=, %); Travel 
diaries (n=, %); questionnaires (n=, %) 
 
12 month follow up 
Workplaces N =  
Participants N =  
Accelerometers (n=, %); GPS (n=, %); Travel 
diaries (n=, %); questionnaires (n=, %) 
  
Withdrawn 
Workplaces N =  
Participants N = 
Withdrawn 
Workplaces N = 
Participants N =  
Withdrawn 
Workplaces N =  
Participants N = 
Workplaces expressing an interest and assessed for 
eligibility (N= ) 
Workplaces consenting (N= ) 
Workplaces withdrawing after consent (N= ):  
Lack of interest from staff (n= ) 
Staff don’t want to wear monitors (n= ) 
Unable to prioritise study (n= ) 
Key contact redundancy (n= ) 
School- too late to start intervention (n= ) 
Not suitable for workplace at present (n= ) 
No reason given (n= ) 
 
Workplaces excluded (N= ):  
Intervention  
Workplaces N =  
Participants N =  
Baseline data collection 
Accelerometers (n=, %); GPS (n=, %); Travel 
diaries (n=, %); questionnaires (n=, %) 
Baseline data collection:  
Workplaces (N= ), Participants (N= ) 
Accelerometers (n=, %); GPS (n=, %); Travel diaries (n=, %); 
questionnaires (n=, %) 
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4.2. BASELINE CHARACTERISTICS 
 
The study cohort will be described by the baseline characteristics in Table 1 (Section 8). These will be 
compared between the two arms by reporting relevant summary statistics in order to determine 
whether any potentially influential imbalance occurred, by chance, between the two arms.  
Characteristics will be reported as means (SD), medians (IQR) or number (%) depending of the 
nature of the data and its respective distribution. For those that follow a symmetrical distribution, 
the mean and standard deviation will be calculated for each group. For those following a skewed 
distribution, the medians (IQR) will be presented for each group. Categorical data will be 
summarised in terms of frequency counts and percentages. 
P-values will not be reported for differences between the two groups at baseline since 
randomisation will have accounted for this. If the baseline characteristics of the intervention and 
control groups differ then the effect of this variable on the outcome will be investigated in a 
sensitivity analysis. 
5. ASSESSMENT OF STUDY QUALITY 
 
5.1. STUDY COMPLETION   
The final follow up, for both arms of the study, is one year after baseline data collection. 
5.2. COMPLIANCE 
The CONSORT diagram (Section 4.1) will give an overview of how many patients left the study. 
Compliance for the primary outcome only is defined as 3 days of valid accelerometer data received by 
each employee.   
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6. ANALYSIS OF EFFECTIVENESS 
6.1 SUMMARY OF THE PRIMARY OUTCOME 
Baseline and one year follow-up MVPA will be collected for both groups. Both group’s MVPA (after 
one year follow up) will be compared using multivariable linear regression with 95% confidence 
intervals, adjusting for baseline MVPA, accelerometer wear-time, randomisation variables (size, 
location and type of workplace) and workplace as a random effect.  
6.2. PRIMARY OUTCOME ANALYSIS 
The null hypothesis for the primary analysis is “no difference in the MVPA” between employees in 
the intervention and control groups at one year’s follow up. Both group’s MVPA levels will be 
compared using multivariable linear regression with 95% confidence intervals. 
𝑦𝑖𝑗 =  𝛽0 +  𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 + 𝛽4𝑥4 + 𝛽5𝑥5 + 𝛾𝑗 +  𝑒𝑖𝑗  
for 𝑖 =1,…,n employees within 𝑗 =1,…,J workplaces, where 𝑒𝑖𝑗  ~ 𝑁(0, 𝜎𝑎
2) and 𝛾𝑗 ~ 𝑁(0, 𝜎𝑏
2) 
Where 𝑦 is MVPA, 𝛽1 is the parameter regression coefficient for treatment group and 𝑥1 is the 
variable for treatment group (1= intervention, 0=control). The following variables (𝑥2, 𝑥3, 𝑥4 and 𝑥5) 
are the potential confounding variables that are being adjusted for. They include baseline MVPA, 
accelerometer wear-time and the size, location and type of workplace. 𝛾𝑗  and 𝑒𝑖𝑗  will adjust for the 
between workplace and within workplace variation, by inclusion of the workplace as a random 
effect.  
The estimated treatment effect will be presented as the adjusted difference in means between the 
intervention and control groups with a 95% confidence interval and p-value. The results of this 
analysis will be recorded in Table 2 (Section 8.3). 
6.3. SECONDARY OUTCOME ANALYSES 
The analysis in Section 6.2 will be adapted to the analysis of other physical activity measures, apart 
from modal shift which will be analysed using a Poisson (or negative binomial, if data is over-
dispersed) regression model. 
- Null hypothesis: “No difference in overall physical activity (counts per minute) between groups” 
- Null hypothesis: “No difference in sedentary time (minutes per day) between groups” 
- Null hypothesis: “No difference in the number of journeys where walking is the main mode of 
travel to/from work between groups” 
- Null hypothesis: “No difference in MVPA due only to the daily commute between groups” 
The results of these analyses will be recorded in Tables 2 and 3 (Section 8.3). 
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6.4. SUBGROUP ANALYSIS 
Subgroup analysis of the primary outcome will explore differences in the effect of intervention 
according to baseline participant age (below or above the median), gender, baseline socioeconomic 
status defined using self-reported household income (below or above £30,000) and distance to work 
(2km or less, more than 2km). These subgroup analyses are exploratory and will be conducted by 
adding interaction terms to the regression models used for the primary analysis. We recognise there 
will be low power for these subgroup analyses and therefore only cautious conclusions will be drawn 
from them. 
The results of these analyses will be recorded in Table 7 (Section 8.5). 
6.5. SENSITIVITY ANALYSIS OF PRIMARY OUTCOME 
- The sensitivity of the results to assumptions about the missing data will be assessed using the most 
appropriate imputation technique for missing primary outcome data (if required).  
- Where there are imbalances in baseline characteristics (Table 1) a sensitivity analysis will be carried 
out for the primary outcome, adjusting for the identified variable. 
- If there is concern that the MVPA distribution is non-normally distributed and therefore the 
multivariable linear regression model is unsuitable, a sensitivity analysis will be investigated using a 
log-transformation of the MVPA outcome.  
- For the primary outcome only (MVPA); different quality assurance thresholds for accelerometer 
data will be investigated (see Section 10) and the primary analysis will be repeated using data from 
working and non-working days independently.  
 
The results of these analyses will be recorded in Tables 4 and 5 (Section 8.4). 
6.6. ANALYSIS OF COSTS AND CONSEQUENCES 
All analyses will be conducted on an intention-to-treat basis comparing the intervention and control 
groups as randomised. The cost-consequence analysis will include the cost of the intervention, 
health care costs, commuting costs, productivity costs and the ICECAP-A. Information needed for 
costing the intervention will be collected by the study team.  
 
Table 7 outlines the cost-consequence table where the final results will be presented. The cost of the 
intervention will be estimated by employee and employer. For the remaining costs and outcomes 
the results will be presented by arm along with the adjusted difference in means between the 
intervention and control groups with a 95% confidence interval and p-value 
 
Missing economic data will be explored and if required a sensitivity analysis will be conducted using 
the most appropriate imputation technique (see Section 3.4 for more details). 
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7. ANALYSIS OF SAFETY 
7.1. ADVERSE EVENTS 
This is a low risk intervention and there were no reported adverse events during the feasibility study. 
However, we will be mindful of the potential for harm in terms of road traffic injuries and collisions, 
personal safety of walkers, difficulties experienced by Walk-to-Work promoters (including disrupting 
usual working relationships and employers attitudes towards time taken out of usual work activities) 
and costs to employers (including disruption to work routines due to permitting the intervention 
during working hours).  
Participating workplaces and Walk-to-Work promoters will have the contact details of the Principal 
Investigator (PI) and will be encouraged to report adverse and serious adverse events which will be 
recorded and reported to the ethics committee.  
If adverse events are attributable to the intervention, relevant participants will be informed 
immediately e.g. other employees taking a similar route. It is also possible that people with low 
activity and no history of walking will suffer initial muscle stiffness. In most cases this would be mild 
and is a normal consequence of increased physical activity. However, participants will be given 
information about symptoms which may require medical attention and temporary or permanent 
cessation of walking to work: for example, where underlying joint weakness is exposed. Such 
incidents will be recorded and monitored throughout the trial. 
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8. FINAL REPORT TABLES AND FIGURES 
 
8.1. SUBJECT CHARACTERISTICS AND BACKGROUND SUMMARIES 
 
Table 1. Baseline characteristics of participants and workplaces  
  Control   Intervention 
 N* Mean (SD), median 
(IQR) or n (%) 
N* Mean (SD), median 
(IQR) or n (%) 
Participant Demographics  
Total number of participants     
Gender: Male     
Age (years)     
BMI: 
Underweight     
Normal     
Overweight     
Obese     
Household income: 
Up to £10,000     
£10,001 - £20,000     
£20,001 - £30,000     
£30,001 - £40,000     
£40,001 - £50,000     
More than £50,000     
Don’t know     
Ethnicity: 
White British     
White other     
Mixed ethnic group     
Asian or British Asian     
Black or Black British     
Chinese     
Other     
Education: 
Higher degree, degree or equivalent     
A levels or equivalent      
GCSEs or equivalent     
No formal qualifications     
Other     
Current method of travel to work 
Car     
Train/Bus     
Walk     
Cycle     
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Distance between workplace and  home (km): 
2km or less     
Over 2km      
Current occupation 
Sedentary     
Standing     
Manual     
Heavy manual work     
Primary outcome 
Daily minutes of MVPA     
Secondary outcomes 
Overall physical activity (counts per 
minute) 
    
Sedentary time (minutes per day)     
Daily minutes of moderate to 
vigorous activity (MVPA) during the 
commute 
    
Number of journeys when walking was the major mode of travel to and from work 
0 journeys     
1 journey     
2 journeys     
3 journeys     
4 journeys     
5 journeys     
6 journeys     
7 journeys     
8 journeys     
9 journeys     
10 journeys     
11 journeys     
12 journeys     
13 journeys     
14 journeys     
Number of valid journeys     
Sensitivity outcomes: Daily minutes of MVPA 
Adjusted quality assurance thresholds 
a) at least 2 weekdays and 1 
weekend day 
    
b) at least 1 day     
Data from working days only     
Data from non-working days only     
Accelerometer wear-time     
Number of valid days      
Workplace demographics 
Total number of employees     
Location 
Swansea (including Newport and 
Neath Port Talbot)  
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Bath (including Swindon)     
Bristol (including South 
Gloucestershire) 
    
Size of business 
Micro     
Small     
Medium     
Large     
Most often used method of travel to work by employees 
Car or motorised transport     
Public transport     
Walk or cycle     
Unknown     
Proportion of employees that walk or cycle all the way to work 
None or hardly any      
Less than half      
Most     
All     
Unknown     
UK SIC Categories 2007 
A: Agriculture, forestry and 
Fishing 
    
B: Mining and quarrying     
C: Manufacturing     
D: Electricity, gas, steam 
and air conditioning 
supply 
    
E: Water supply; sewerage, 
waste management and 
remediation activities 
    
F: Construction     
G: Wholesale and retail 
trade; repair of motor 
vehicles and motor 
cycles 
    
H: Transport and storage     
I: Accommodation and 
food service activities 
    
J: Information and 
Communication 
    
K: Financial and insurance 
Activities 
    
L: Real estate activities     
M: Professional, scientific 
and technical activities 
    
N: Administrative and 
support service activities 
    
O: Public administration 
and defence; compulsory 
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social security 
P: Education     
Q: Human health and social 
work activities 
    
R: Arts, entertainment and 
Recreation 
    
S: Other service activities     
T: Activities of households 
as employers; 
undifferentiated goods and 
services-producing 
activities of households 
for own use 
    
U: Activities of 
extraterritorial 
organisations and bodies 
    
*Total number of employees or employers (as appropriate) that responded to this question (those with missing values excluded) 
 
8.2. STUDY QUALITY SUMMARIES 
Summarised in the CONSORT chart (see Section 4.1) 
 
8.3. OUTCOME SUMMARIES 
 
Table 2. Continuous outcome analyses  
Outcome Control mean 
(SD) 
Intervention 
mean (SD) 
Adjusted 
difference in 
means* (95% 
CI) 
Additionally 
adjusted 
difference in 
means**(95% 
CI) 
P-value 
Primary 
i) Daily minutes of 
MVPA 
     
Secondary 
ii) Overall physical 
activity (counts per 
minute) 
     
iii) Sedentary time 
(minutes per day) 
     
iv) Daily minutes of 
moderate to vigorous 
activity (MVPA) during 
the commute 
     
*Adjusted for baseline outcome 
**Adjusted for size, location and type of business, baseline outcome, accelerometer wear-time (for outcomes i and iii) and workplace as 
a random effect. 
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Table 3. Categorical outcome analyses  
Outcome Control 
participants N 
(%) 
Intervention 
participants N 
(%) 
Adjusted 
incidence rate 
ratios* (95% CI) 
Additionally 
adjusted 
incidence rate 
ratios**(95% CI) 
P-value 
Secondary 
v) Number of journeys when 
walking was the major mode of 
travel to and from work 
     
0 journeys      
1 journey      
2 journeys      
3 journeys      
4 journeys      
5 journeys      
6 journeys      
7 journeys      
8 journeys      
9 journeys      
10 journeys      
11 journeys      
12 journeys      
13 journeys      
14 journeys      
*Adjusted for baseline outcome 
**Adjusted for size, location and type of business, baseline outcome and workplace as a random effect. 
 
 
8.4. SENSITIVITY ANALYSES 
 
Table 4. Sensitivity analyses of primary outcome 
Outcome 
Control mean 
(SD) 
Intervention 
mean (SD) 
Adjusted 
difference in 
means* (95% CI) 
Additionally 
adjusted 
difference in 
means* 
(95% CI) 
P-value 
Daily minutes of MVPA 
Additionally 
adjusted for 
imbalances in 
baseline 
characteristics 
  
 
 
 
Imputation of 
missing data (if 
appropriate)  
  
 
 
 
Adjusted quality assurance thresholds 
a) at least 2 
weekdays and 1 
weekend day 
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b) at least 1 day      
Data from 
working days only 
  
 
 
 
Data from non-
working days only 
  
 
 
 
*Adjusted for baseline daily minutes of MVPA 
**Adjusted for size, location and type of business, baseline daily minutes of MVPA, accelerometer wear-time and workplace as a random 
effect. 
 
Table 5. Sensitivity analysis of primary outcome (if non-normally distributed) 
Outcome 
Control log-
mean (SD) 
Intervention 
log-mean (SD) 
Adjusted ratio 
of geometric 
means* (95% 
CI 
Additionally 
adjusted ratio 
of geometric 
means** 
(95% CI) 
P-value 
Daily minutes of MVPA 
Linear regression of log-
transformed outcome 
   
 
 
*Adjusted for baseline daily minutes of MVPA 
*Adjusted for size, location and type of business, baseline daily minutes of MVPA, accelerometer wear-time and workplace as a 
random effect. 
s 
 
8.5. SUBGROUP ANALYSIS  
Table 6. Subgroup analysis of primary outcome 
Outcome 
Control 
mean (SD) 
Intervention 
mean (SD) 
Adjusted 
difference in 
means* 
(95% CI) 
Additionally 
adjusted 
difference in 
means** 
(95% CI)  
Interaction 
P-value   
Daily minutes of MVPA in each subgroup 
Age (<median)       
Age (≥median)      
Sex (Male)      
Sex (Female)      
Household income (below £30,000)      
Household income (above £30,000)      
Distance from work (2km or less)      
Distance from work (more than 2km)      
*Adjusted for baseline daily minutes of MVPA 
*Adjusted for size, location and type of business, baseline daily minutes of MVPA, accelerometer wear-time and workplace as a 
random effect. 
 
8.6. ECONOMIC RESULTS 
Table 7. Cost-consequence analysis 
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 Intervention Control Adjusted incremental 
difference 
Intervention costs:    
Average intervention cost 
per participating employee 
 
 
 
Average intervention cost 
per workplace 
 
 
 
Health care cost    
Commute cost    
Productivity cost    
ICECAP-A    
 
8.7. SAFETY RESULTS 
Table 8. Adverse events 
 Control N (%) Intervention N (%) 
Severity:   
Not Serious   
Serious unexpected   
Serious expected   
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10. ACCELEROMETRY AND GPS; DECISIONS AND OUTCOMES 
 
  
 Accelerometry: decisions and outcomes 
Initialising Accelerometers initialised to start recording on day after distribution and to 
store data for 7 days including a weekend.  
Data collection points Baseline (DC1), one year follow-up (DC3) 
Protocol Single Actigraph GT1M monitor, worn around the waist over the same hip 
during waking hours (except when swimming/bathing/showering). 
Wear time Waking hours  
Valid length of day ≥10 hours (600 minutes) for primary analysis 
Days required Primary analysis: Any 3 days (for outcomes i, ii and iii), 1 day (outcome iv and v) 
Sensitivity analysis (outcome i only): a) at least 2 weekdays and 1 weekend day, 
b) at least 1 day 
Epoch length 10 seconds 
Zero counts Bouts of 60 minutes of continuous/consecutive zero counts excluded 
Spurious data ≥ 20,000 cpm 
Activity cut-points Sedentary <100 cpm ; MVPA ≥ 1952 cpm40 
Outcomes i) Moderate to vigorous physical activity (MVPA) 
ii) Sedentary time 
iii) Overall physical activity, mean counts per minutes (cpm) 
iv) Modal shift (number of journeys when walking was main mode of travel 
to/from work) 
v) Moderate to vigorous physical activity (MVPA) during the commute 
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 GPS: decisions and outcomes 
Initialising GPS records when switched on 
Data collection points Baseline (DC1), one year follow-up (DC3) 
Protocol Switch on to ‘log’ before leaving for work. Switch to ‘off’ when finishing the 
commute. 
Wear time Commute and working hours  
Valid data One journey on given day required 
Days required 1 valid working day 
Spurious data Aberrant speed: all GPS points recorded as travelling at more than 100 kph 
Outliers for each participant: removal of GPS points that are further than 500 
metres from any other GPS points  
Missing data Use mode of travel from self-reported travel diary  
Outcomes iv) Modal shift (number of journeys when walking was main mode of travel 
to/from work) 
v) Moderate to vigorous physical activity (MVPA) during the commute 
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